Rapidemic receives $2.7 million grant to improve rapid STI diagnostics
Rapidemic, based in Leiden Bio Science Park, has received €2.7 million in funding from the Bill & Melinda Gates Foundation. This amount is intended for the further development of their rapid test for detecting the sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae. With this support, the company can further improve the innovative test and scale up production.
The test is unique in that it provides reliable results on the presence of STDs at room temperature and in just 15 minutes. Thanks to this approach, costly and complex equipment is no longer necessary. This makes the test ideal for use in countries with limited medical infrastructure. In such areas, rapid diagnosis is often difficult due to a lack of appropriate facilities.
Rapidemic wants to use its technology to enable people anywhere in the world, regardless of their location or access to laboratories, to be tested quickly and easily. This can make a big difference in reducing infections and improving the treatment and living conditions of patients.
Rapidemic is thus taking an important step towards improving global health in STD diagnostics.
